drugset / Trial / NCT03398122
Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC
Timeline
- Start
- 2017-11-14
- Primary completion
- 2018-10-01
- Completion
- 2019-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 250 mg | — |